Nicotinamide Riboside Interactions: Alcohol, Caffeine, Food and Other Compounds

Questions about how nicotinamide riboside (NR) behaves alongside alcohol, coffee, meals, fasting windows or other supplements are common, but the published record answers far fewer of them than the questions imply. This page separates three different things: findings that studies actually reported, adjacent findings from studies that did not test the combination in question, and the mechanistic reasoning researchers use when no interaction study exists. A broader background on the molecule is available in the nicotinamide riboside overview.

What "interaction" means in nicotinamide riboside research

NR is a pyridine nucleoside precursor to nicotinamide adenine dinucleotide (NAD+). A 2014 review in Trends in Cell Biology described the relationship between NAD+ and sirtuins in aging and disease, framing NAD+ as both a redox cofactor and a substrate consumed by signalling enzymes (PMID 24786309). A 2018 Cell Metabolism review assessed the in vivo evidence for NAD-boosting molecules across preclinical and early clinical work (PMID 29514064), and a 2024 Sub-cellular Biochemistry chapter reviewed NAD+ boosting strategies more broadly (PMID 39693020).

Interaction questions generally fall into two categories. Pharmacokinetic questions ask whether another substance changes how much NR is absorbed, converted or cleared. Pharmacodynamic questions ask whether two substances push the same biological system in the same or opposite directions. Reviews of NAD+ boosting strategies have mapped the conversion routes that such questions depend on (PMID 39693020), but mapping a pathway is not the same as testing a combination — a distinction that matters for every section below.

Alcohol and nicotinamide riboside

What the verified literature examined

None of the studies in this citation set administered NR together with ethanol, in humans or in animals. The closest liver-relevant work is a 2019 cell study in Nutrition Research and Practice, in which researchers reported that NR regulated inflammation and mitochondrial markers in AML12 hepatocytes (PMID 30788050). That was an isolated mouse hepatocyte line, not an alcohol-exposure model, so the study cannot be read as evidence about drinking.

Mechanistic reasoning (labelled as reasoning, not evidence)

The reasoning researchers apply is straightforward textbook biochemistry: ethanol oxidation by alcohol dehydrogenase and aldehyde dehydrogenase reduces NAD+ to NADH, shifting the cytosolic NAD+/NADH ratio. Because reviews have characterised NAD+ as a shared redox currency and a consumed substrate (PMID 24786309), it is mechanistically plausible that heavy ethanol exposure and NAD+ precursor availability intersect. Plausibility is where the published record in this set stops; the 2018 in vivo evidence review catalogued NAD-boosting outcomes without establishing an alcohol interaction result (PMID 29514064).

Caffeine and nicotinamide riboside

No study among the verified papers examined caffeine, coffee or tea alongside NR. There is no pharmacokinetic comparison, no reported change in NR conversion with caffeine co-exposure, and no clinical signal to summarise.

The mechanistic reasoning researchers offer — again, reasoning rather than data — rests on the fact that caffeine is a methylxanthine cleared largely by hepatic cytochrome P450 enzymes, while NR is handled by dedicated nucleoside kinase and salvage routes described in NAD+ boosting reviews (PMID 39693020). Separate handling routes make a direct competitive interaction less likely on paper, but this has not been tested. One cardiac study did place a nicotinamide riboside kinase at the centre of its findings, reporting an NMRK2-YAP-NADK axis that preserved redox protection against myocardial ischaemia/reperfusion injury (PMID 41762891) — relevant to how NR is processed, and unrelated to caffeine.

Food, meals and fasting

The verified set contains no fed-versus-fasted pharmacokinetic comparison for NR. What it does contain is dietary context. A 2023 review in Current Nutrition Reports examined nicotinamide mononucleotide (NMN) and NR as NAD+ precursors with a potential dietary contribution to health (PMID 37273100), which is the framing researchers use when discussing precursors that also occur in foods. A 2023 paper in Food Research International described biotechnological production of reduced and oxidized NAD+ precursors (PMID 36869544), underlining that different chemical forms of the same precursor family exist and are studied separately.

Because the reduced and oxidized forms differ chemically (PMID 36869544), researchers have cautioned that findings about one form do not automatically transfer to another — a point that also limits how far dietary-source data can be extended to isolated preparations (PMID 37273100).

Other compounds examined alongside NR

Other NAD+ precursors

This is the one genuine combination finding in the verified set. A 2022 Nutrients study reported that NR and dihydronicotinic acid riboside synergistically increased intracellular NAD+ by generating dihydronicotinamide riboside (PMID 35807932). The study was conducted in cells, and its result describes a chemical and metabolic interaction between two precursors rather than an outcome in people.

Sirtuins and NAD+-consuming enzymes

Because sirtuins use NAD+ as a substrate, compounds that engage sirtuins are frequently raised in combination questions. A 2023 paper in The FEBS Journal reported that nicotinamide riboside activated SIRT5 deacetylation (PMID 37289138), and the 2014 review set out the wider NAD+–sirtuin relationship in aging and disease (PMID 24786309). Neither examined NR combined with a separate sirtuin-targeting supplement.

Methyl donors and methionine metabolism

A recurring mechanistic argument is that nicotinamide disposal involves methylation, linking NAD+ precursors to methionine metabolism. The verified set includes a 2025 Cell Metabolism study reporting that homocysitaconate controlled inflammation through reshaping methionine metabolism and N-homocysteinylation (PMID 40876449); that study did not test NR, so it illustrates the biology researchers invoke rather than confirming a methyl-donor interaction with NR.

Immunometabolism

Metabolite-driven immune modulation is another adjacent area. A 2025 Nature Immunology study reported that targeting lactylation reinforced natural killer cell cytotoxicity within the tumour microenvironment (PMID 40494934). It did not involve NR, and is included here only to show why cofactor and metabolite availability is discussed in immune contexts.

Cardiac and mitochondrial models

Two cardiac papers are often cited when combination questions arise in cardiometabolic settings. A 2018 Circulation study reported that nicotinamide riboside preserved cardiac function in a mouse model of dilated cardiomyopathy (PMID 29217642), and the 2026 Redox Biology study reported that the NMRK2-YAP-NADK axis preserved redox protection against myocardial ischaemia/reperfusion injury (PMID 41762891). Neither was a drug-interaction study, and neither tested co-administration with cardiovascular medications.

Interaction questions mapped against the evidence

Adverse Events and Interaction Signals: What Studies Report

The verified set does not include a dedicated interaction or drug-safety trial for NR. The 2018 in vivo evidence review assessed NAD-boosting molecules across animal and early human work and framed their therapeutic potential alongside the limits of the available data (PMID 29514064), while the 2024 review of NAD+ boosting strategies similarly surveyed the field without reporting a combination-specific adverse-event dataset (PMID 39693020). Where a page like this cannot point to a reported adverse event from a co-administration study, the accurate statement is that none exists in the cited literature — not that a combination is benign.

How researchers describe the gaps

• Model type matters. The synergy result between precursors was an intracellular NAD+ measurement (PMID 35807932), and the cardiac result came from a mouse disease model (PMID 29217642).
• Chemical form matters. Reduced and oxidized precursors are produced and studied as distinct molecules (PMID 36869544).
• Pathway maps are not interaction data. Reviews describing NAD+ salvage and boosting routes explain plausibility rather than demonstrate co-administration outcomes (PMID 39693020).
• Adjacent metabolism is not NR evidence. Work on methionine metabolism (PMID 40876449) and lactylation in immune cells (PMID 40494934) did not involve NR.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any compound, combination, medication or health condition. It summarises what the cited papers reported and does not describe how any substance should be used.

References

• NAD+ and sirtuins in aging and disease (Trends in Cell Biology, 2014)
• Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence (Cell Metabolism, 2018)
• NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (Current Nutrition Reports, 2023)
• NAD(+) Boosting Strategies (Sub-cellular Biochemistry, 2024)
• Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy (Circulation, 2018)
• NMRK2-YAP-NADK axis preserves redox protection against myocardial ischemia/reperfusion injury (Redox Biology, 2026)
• Nicotinamide riboside activates SIRT5 deacetylation (The FEBS Journal, 2023)
• Biotechnological production of reduced and oxidized NAD(+) precursors (Food Research International, 2023)
• Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase Intracellular NAD(+) by Generating Dihydronicotinamide Riboside (Nutrients, 2022)
• Homocysitaconate controls inflammation through reshaping methionine metabolism and N-homocysteinylation (Cell Metabolism, 2025)
• Nicotinamide riboside regulates inflammation and mitochondrial markers in AML12 hepatocytes (Nutrition Research and Practice, 2019)
• Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment (Nature Immunology, 2025)